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ABSTRACT
Familial adenomatous polyposis (FAP) is rare affecting 1 in 10,000 people and a 
subset (10%) are at risk of myofibroblastic desmoid tumours (DTs) after colectomy 
to prevent cancer. DTs are a major cause of morbidity and mortality. The absence 
of markers to monitor progression and a lack of treatment options are significant 
limitations to clinical management. We investigated microRNAs (miRNA) levels in 
DTs and serum using expression array analysis on two independent cohorts of FAP 
patients (total, n=24). Each comprised equal numbers of patients who had formed 
DTs (cases) and those who had not (controls). All controls had absence of DTs 
confirmed by clinical and radiological assessment over at least three years post-
colectomy. Technical qPCR validation was performed using an expanded cohort (29 
FAP patients; 16 cases and 13 controls). The most significant elevated serum miRNA 
marker of DTs was miR-34a-5p and in-situ hybridisation (ISH) showed most DTs 
analysed (5/6) expressed miRNA-34a-5p. Exome sequencing of tumour and matched 
germline DNA did not detect mutations within the miR-34a-5p transcript sites or 
3’-UTR of target genes that would alter functional miRNA activity. In conclusion, 
miR-34a-5p is a potential circulatory marker and therapy target. A large prospective 
world-wide multi-centre study is now warranted.
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INTRODUCTION
Desmoid tumours (DTs) are rare myofibroblastic, 
soft tissue tumours. The majority (90%) are caused 
by mutations in the CTNNB1 β-catenin gene and occur 
sporadically [1, 2]. In contrast, the remaining 10% are 
found in association with familial adenomatous polyposis 
(FAP), a rare autosomal dominantly inherited condition 
affecting about 1 in 10,000 people. FAP patients have 
a germline mutation in one allele of the adenomatous 
polyposis coli (APC) tumour suppressor gene. Mutations 
of APC lead to abnormal activation of the Wnt signalling 
pathway and tumour formation, notably in the colon and 
rectum [3, 4].  
FAP is characterised by the formation of hundreds 
to thousands of colorectal adenomas that progress to 
colorectal cancer in nearly all affected individuals if 
they do not undergo prophylactic colectomy [5]. Patients 
with FAP are also at increased risk of other tumours, 
including duodenal adenomas and carcinomas, and DTs, 
which have a prevalence of 10–20% in FAP arising with 
a frequency approximately 850 times that of the general 
population [6]. DTs are a major cause of morbidity and 
mortality in FAP patients but can also occur sporadically 
in the general population [7, 8]. Trauma from prophylactic 
colectomy (most DTs arise within the first few years after 
prophylactic colectomy), APC germline mutations 3’ of 
codon 1399 and unknown genetic factors independent of 
APC are significant risk factors for DT development [9, 
10].
FAP associated DTs can occur anywhere in 
the body, although most develop in the small bowel 
mesentery and abdominal wall, and are locally 
infiltrative [11]. The majority are found incidentally 
on cross sectional imaging, or present as a mass, and 
do not cause significant problems. However, some 
grow aggressively, invading local surrounding tissues 
and causing complications including bowel and ureter 
obstruction, fistulation, abdominal sepsis and even death 
[7]. There is a low threshold for radiological imaging to 
assess FAP associated DT development, particularly after 
surgery, and multiple imaging studies are often required 
following a diagnosis of intra-abdominal DT to assess 
growth and accompanying complications [12]. Treatment 
is difficult, with anti-oestrogens and NSAIDs frequently 
used as first line therapy, but without any good quality 
evidence of efficacy. Cytotoxic chemotherapy can be used, 
but ultimately some patients require surgery, which often 
results in extensive small bowel resection and long-term 
parenteral nutrition requirement in complex cases [7].
DTs represent the greatest challenge in the 
management of FAP and there is a significant unmet 
clinical need for biomarkers to provide early indication 
of DTs, particularly the presence of intra-abdominal DTs 
that may not be obvious at clinical examination, and to 
predict subsequent aggressive growth. Such markers 
could also act as an adjunct in determining timing of 
surgery and reducing frequency of radiological imaging, 
and in monitoring response to treatment. Investigations 
to identify biomarkers also have the potential to identify 
novel targets for therapy. However, large-scale biomarker 
studies are hampered significantly by the extremely 
low prevalence of FAP DTs (1/100 000 of the general 
population). Identifying appropriate controls (FAP patients 
who do not form DTs) is also clinically challenging, as it 
is difficult to verify that they represent genuine controls: 
FAP patients often only form DTs following surgery and 
are not routinely screened for DTs. Significant resources 
and follow-up will be necessary to rule-out DT formation 
in any future prospective trial.
MicroRNAs (miRNAs) are short non-coding 
RNA molecules that regulate post-transcriptional gene 
expression and cellular activities including fibrosis and 
tumour development. Abnormal expression of specific 
miRNA molecules has been implicated in the development 
of fibrotic disorders, for example miR-29 in cardiac 
fibrosis [13] and more recently fibrostenosing Crohn’s 
disease, which is characterised by intestinal fibrosis 
[14]. MiRNAs also play a role in cancer development 
and metastasis, functioning as tumour suppressors or 
oncogenes [15, 16]. Circulating miRNAs can act as non-
invasive biomarkers of fibrosis [14, 16] and as novel 
treatment targets through the use of miRNA antagonists 
[17]. In this study we test the feasibility and potential 
utility of circulating miRNAs in serum to act as non-
invasive biomarkers of rare FAP-associated DTs, and also 
assess the levels of the most promising miRNA within the 
tumours. 
RESULTS
Patient characteristics
Patients with a diagnosis of FAP with DT and with 
follow-up at a single institution were identified from the 
institution polyposis registry database (St Mark’s Hospital, 
Harrow), the largest such registry in Europe, and the 
second largest in the world. Every diagnosis of DT was 
confirmed on cross sectional imaging (CT or MRI). Serum 
samples were obtained from individuals with FAP and DT, 
and control samples acquired from FAP patients with both 
clinical and radiological confirmation of DT absence. All 
control participants were recruited at least 3 years after 
their prophylactic colectomy, beyond the time when a DT 
was most likely to be detected [10]. Patient records were 
analysed to ensure none of the control participants had a 
previous history of DT. Table 1 compares demographic 
data between the identified FAP DT cases and FAP 
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Table 1. Demographic data comparing FAP desmoid tumour and FAP controls
FAP-controls  
n (%)
DT cases 
n (%)
p-value
Gender
Male
Female
7 (54)
6 (46)
11 (69)
5(31)
0.466*
Age at time of study 
(median years)
44
(22-72)
38
(20-64) 0.308**
APC mutation 3’ 1399
Yes
No
 
1 (8)
12 (92)
7 (44)
9 (56)
0.044*
*Fisher’s exact test, ** Mann Whitney-U test
Table 2. miRNAs that differentiate desmoid tumour patients from FAP controls in cohort 1
Mature ID p-value Fold change (Log2)
hsa-miR-1287-5p 0.003 -0.464
hsa-miR-34a-5p 0.007 2.288
hsa-miR-532-5p 0.008 1.790
hsa-miR-29c-5p 0.008 1.922
hsa-miR-142-5p 0.010 2.655
hsa-miR-382-5p 0.014 1.324
hsa-miR-143-3p 0.015 2.179
hsa-miR-145-5p 0.022 1.870
hsa-miR-2467-3p 0.030 -0.954
hsa-miR-3120-3p 0.031 1.820
hsa-miR-101-3p 0.033 2.106
hsa-miR-19b-3p 0.035 1.885
hsa-miR-637 0.041 -1.137
hsa-miR-133b 0.042 0.939
hsa-miR-19a-3p 0.044 1.768
hsa-miR-4687-5p 0.045 -1.014
hsa-miR-4688 0.045 -1.198
hsa-miR-4770 0.046 1.465
hsa-miR-503-5p 0.047 1.516
hsa-miR-324-5p 0.047 2.352
hsa-miR-339-3p 0.048 2.139
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controls. The overall median age of participants was 43 
years (range 20-72). There was no significant difference 
between controls and DT formers in terms of gender 
and age. Unsurprisingly, the proportion of patients with 
an APC mutation 3’ of codon 1399 was significantly 
higher in the DT group compared to controls (p=0.044). 
Mutations in this region are a recognised risk factor for 
DT development [10]. 
Comparison of patient serum from DT cases and 
FAP controls identifies differentially expressed 
microRNAs 
Qiagen determined the levels of 384 miRNAs in the 
serum of patients with FAP by array profiling. Data were 
normalised to an exogenous spiked in control probe (Cel-
miR-39) and no significant haemolysis was detected in any 
of the samples (Supplementary Figure 1). Two cohorts of 
FAP patients (24 patients in total) with and without DTs 
(n=6 of each in both cohorts) were assessed. Each cohort 
was processed and analysed independently in two separate 
batches. Comparison of miRNA levels in serum of FAP 
controls and DT cases identified a number of differentially 
expressed miRNAs in each cohort (Table 2 and 3). Only 
one miRNA, miR-34a-5p, was found to be independently 
associated with DTs in both cohorts; serum levels of 
miR-34a-5p were increased in DT patients relative to 
FAP controls. Moreover, the association of miR-34a-5p 
with DTs was even stronger when the data for the two 
cohorts were combined to increase statistical power. In 
total, the combined analysis identified nine differentially 
expressed miRNAs, all of which were increased in DTs 
relative to FAP controls. Of these, miR-34a-4p was the 
most significant, whilst increased levels of miR-29c-5p 
were also strongly associated with the presence of DTs in 
the FAP population (Table 4, Figure 1). However, in this 
combined analysis statistical significance was lost once a 
stringent Bonferroni correction was applied to correct for 
multiple testing. 
Altered serum microRNA level profiles in patients 
with aggressively growing and quiescent desmoids
In a separate sub-analysis of the array data, serum 
miRNA level profiles within the whole DT population 
(n=12) were compared between patients with aggressively 
growing (n=3) and quiescent DTs (n=9). Aggressive 
tumours were defined as those with evidence of clinical 
and radiological growth with associated complications, 
e.g. bowel obstruction, perforation or ureteric obstruction 
within a six-month period prior to taking the serum 
sample. Stable tumours were defined as those without 
clinical or radiological change in tumour growth over 
the previous 24 months. This comparison identified three 
miRNAs with an unadjusted p-value ≤0.05. The most 
significantly differentially expressed miRNA between 
these two groups was miR-3646, which was decreased in 
the serum of patients with aggressive DTs (Supplementary 
Table 1).
Differentially expressed microRNAs in sera are 
validated by qPCR
To validate the array, miR-34a-5p and miR-29c-
5p were quantified by single qPCR assays as markers of 
DTs in the FAP population; levels of miR-3646 were also 
assessed as a marker of aggressive DTs. The qPCR cohort 
(13 FAP controls and 16 DT cases comprising 12 quiescent 
DTs and 4 aggressive DTs), although expanded in number, 
included the samples previously analysed by array. Hence, 
the qPCR analysis acts as an important technical validation 
with samples from both array cohorts run in a single batch. 
As for the array, miRNA levels for this analysis were 
normalised to an exogenous spiked-in control. Initial 
analyses identified a statistical outlier in the FAP control 
group following comparison of miR-34a-5p levels in DTs 
and FAP control groups (Supplementary Figure 2); this 
sample was therefore excluded. After adjusting for this 
single outlier in the control group, greater discrimination 
was possible between DTs and FAP controls and a 
significant increase in miR-34a-5p in both quiescent and 
aggressive DTs was detected in line with the results of 
the array (p=0.019 and p=0.007, respectively, Figure 2A). 
Figure 1. Heatmap comparing serum miRNA levels between 
desmoid tumour patients and FAP controls. Data are presented 
as a log2 fold change relative to the mean of FAP controls. The 
Y axis lists miRNAs altered in the sera of DT patients relative 
to FAP controls ranked in ascending order according to p-value. 
The x-axis lists the sample identifiers.
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Table 3. miRNAs that differentiate desmoid tumour patients from FAP controls in cohort 2.
Mature ID p-value Fold change (Log2)
hsa-miR-34a-5p 0.011 1.909
hsa-miR-328-3p 0.014 2.011
hsa-miR-138-1-3p 0.020 1.090
hsa-miR-631 0.021 1.281
hsa-miR-4302 0.033 -0.856
hsa-miR-1231 0.034 1.626
hsa-miR-1207-5p 0.042 1.821
hsa-miR-629-3p 0.046 0.872
hsa-miR-1180-3p 0.048 -0.711
Table 4. miRNAs that differentiate desmoid tumour patients from FAP controls in a combined analysis 
of cohorts 1 and 2.
Mature ID p-value Fold change (Log2)
hsa-miR-34a-5p 0.001 2.099
hsa-miR-29c-5p 0.003 1.531
hsa-miR-142-5p 0.008 1.584
hsa-miR-532-5p 0.011 1.045
hsa-miR-1287-5p 0.013 -0.369
hsa-miR-328-3p 0.013 2.210
hsa-miR-1207-5p 0.016 1.128
hsa-miR-1231 0.018 1.400
hsa-miR-4505 0.033 0.969
Table 5. ISH miR staining scores for aggressive and stable DTs.
Phenotype/case
Weighted staining score
miR-21-5p miR-34a-5p
Aggressive A Level A Level
1 130 high 200 high
2 120 high 165 high
3 0 none 110 low
4 0 none 0 none
Stable
5 35 low 170 high
6 0 none 140 high
The weighted score is: (1 x the percentage staining at intensity 1) + (2 x the percentage staining at intensity 2) + (3 x the percentage staining 
at intensity 3). A weighted score of 120 or more is then arbitrarily defined as high level staining.
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In contrast, levels of miR-29c-5p were only significantly 
elevated in the aggressive DT group compared to FAP 
controls (p=0.017, Figure 2B). However, contrary to the 
array findings, the single qPCR assay failed to show any 
significant difference in the level of circulating miR-3646 
between patients with an aggressive DT compared to those 
with a stable one (Figure 2C). 
MicroRNA in situ hybridisation detects 
substantial miR-34a-5p expression in desmoid 
tumours 
Analysis of serum identified miR-34a-5p as the 
most significant marker of DT formation. We therefore 
sought to determine whether miR-34a-5p was expressed 
within DTs (n=6) using sections cut from FFPE tissue 
sections and ISH miRNA technology. The expression of 
miR-34a-5p in DTs was compared to miR-21a-5p, which 
acted as a positive control for staining, given its reported 
expression in fibroblasts and involvement in fibrosis [18, 
19]. In 5 of the 6 tumours miR-34a-5p was expressed 
(high expression in 4/5; low expression in 1/5, but close to 
the arbitrary high/low cut-off; Table 5). Positive staining 
for miR-21a-5p was also observed in 3/6 DTs (Figure 3A; 
Table 5), whereas, healthy skin control tissue sections 
were negative for these probes (Figure 3A). In this small 
cohort, the intensity of staining for miR-34a-5p and miR-
21a-5p were not correlated with the aggressiveness of the 
DTs (p=0.8, p>0.99, and p=0.8, respectively) (Figure 3B). 
Levels of P53 were also investigated in serial sections, 
as it is known to induce miR-34a-5p expression. There 
was no nuclear p53 expression in 2/6 tumours analysed, 
low expression in 3/6 tumours and high expression in one 
aggressive DT (Figure 4A; Supplementary Table 2). In 
these sections, there was no direct correlation between p53 
staining intensity and miR-34a-5p staining (Spearman’s 
rank correlation coefficient of 0.3, p=0.567) (Figure 4B). 
No somatic mutations in miR-34a-5p transcript 
sites or target 3’ UTR in desmoid tumours
Whole exome sequencing was performed in three 
tumour-germline pairs of DT formers at an average 
coverage of ~30x. We interrogated the sequencing data 
for somatic or loss of heterozygosity mutations within the 
miRNA transcript sites as well as the binding sites of the 
miRNA target genes. There were no detected mutations 
or alterations within the miR-34a-5p transcript sites that 
would contribute to the altered miRNA activity in DT. We 
investigated whether somatic mutations occurring in 3’-
UTR of the miRNA target genes alter an existing miRNA 
binding site, interfering with miRNA dependent gene 
regulation. A list of the miRNA target genes interrogated is 
provided in the Supplementary Table 3 as predicted by the 
TargetScan algorithm [20]. We found no mutations in the 
3’UTR of target genes of miR-34a-5p that would disrupt 
the miRNA binding sites. There is therefore no evidence 
of tumour alterations that would indicate that the tumour 
is escaping the action of the miRNA. This observation 
is in agreement with previous studies that suggest that 
somatically acquired mutations in miRNA genes or their 
target 3’ UTR are infrequent in tumour samples [21-23]. 
Figure 2. Box and whisker plot comparing serum miRNA levels in desmoid tumour patients and FAP controls. The p values for comparisons 
to FAP controls are stated on the graphs. No significant differences between quiescent and aggressive DTs were observed.
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DISCUSSION
DTs are the largest challenge in the management 
of FAP and biomarker studies are invariably hampered 
significantly by the extremely low prevalence of FAP DTs. 
We have secured serum and DTs for this study from the 
St Mark’s Polyposis Registry, the largest such registry in 
Europe, and the second largest in the world. Our study 
has explored differentially expressed miRNAs in the sera 
of FAP patients with and without DTs. In this study two 
independent cohorts of extensively phenotyped patients 
were analysed, and a technical qPCR validation analysis 
with all samples run in a single block was performed. 
This analysis identified increased levels of miR-34a-5p 
as a marker of DT in the FAP population in both cohorts 
analysed, and this was confirmed by qPCR. However, the 
current clinical utility of miR-34a-5p, as a non-invasive 
biomarker of DTs in the FAP population, is likely limited 
due to the observed overlap in levels of miR-34a-5p 
between DT-formers and FAP controls. 
Altered tissue miRNA profiles within largely 
sporadic DTs have previously been associated with 
aggressive DTs [24]. In this study the potential of 
serum miRNA markers for identification of aggressive 
DTs was therefore also explored. Analysis of the array 
data identified only three miRNAs that were altered in 
aggressive DTs relative to quiescent tumours; of which, 
miR-3646 was the most significant. However, due to the 
relatively low number of aggressive DTs analysed (n=3) 
and the high number of miRNAs analysed all statistical 
significance was lost once the p-values were adjusted for 
multiple testing. Moreover, difference in miR-3636 could 
not be validated by qPCR. The low validation frequency 
for miRNA markers of tumour aggressiveness likely 
reflects the comparatively low number of aggressive 
DTs analysed. The low number of samples highlights the 
difficulty in obtaining well phenotyped samples (both 
controls and cases) for rare diseases such as FAP; FAP 
patients with DTs are an even rarer group of patients (1/100 
000 of the general population). Unfortunately, additional 
samples would require a major collaborative effort 
across FAP management centres world-wide to combine 
expertise and resources to maximise sample numbers. 
Nevertheless, given the severity and refractory nature of 
the disease biomarker investigations are of importance: 
potential applications of non-invasive biomarkers of DT 
could include earlier detection, and identification of more 
aggressive tumour phenotypes to enable swift institution 
of medical therapy. Early identification of DT patients 
would also prompt closer follow-up, particularly for 
aggressive DTs. A reliable biomarker that reflected DT 
growth could also reduce the frequency of radiological 
imaging to assess stable tumours. The findings of this 
study should provide the impetus for further research in 
this area and in fibrosis in general. 
Attempts to study miRNAs levels in DT tissue were 
also made in this study. There are a number of difficulties 
in quantitatively assessing expression levels in DTs, not 
least the lack of an appropriate control tissue and DT 
cell lines. In this study miRNA levels in DT tissue were 
investigated using miRNA ISH techniques. This analysis 
demonstrated that miR-34a-5p is highly expressed by 
DTs relative to other miRNAs known to be involved in 
cancer and fibrosis e.g. miR-21a-5p. In this small cohort, 
the intensity of miR-34a-5p staining in DTs was not 
correlated with the aggressiveness of the tumour, nor 
were they correlated with P53 levels, which are known to 
directly induce miR-34a-5p expression in other systems 
[25]. Moreover, exome sequencing did not detect any 
mutation in the transcription sequence of miR-34a-5p or 
in the 3’UTRs of target mRNAs that might disrupt this 
miRNAs activity in DTs. 
 These data raise two important possibilities; one, 
that miR-34a-5p has a functional role in the growth of 
these tumours, and two, that the increase in miR-34a-5p 
in the serum may originate from the DT. 
Targets of miR-34a include several genes in the Wnt 
Figure 3. In Situ Hybridisation for miR-34a-5p A. (a) and 
miR-21a-5p (b) in desmoid tumours and miR-34a-5p (c) and 
miR-21a-5p (d) in normal skin. High expression of miRNA-
34a-5p and miR-21a-5p seen in the desmoid tumour from 
patient 1 (Table 5) compared to weak staining both of the skin 
controls. Purple cytoplasmic staining (black arrow) represents 
positive staining for the relevant miRNA and pink negative. 
Magnification x20 and x40. B. Comparison of miR-34a-5p, 
miR-21-5p mean staining scores in aggressive and stable 
desmoid tumours. *Mann Whitney-U test
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signalling pathway, which is integral for DT development. 
For example, the p53/miR-34 axis is known to suppress 
the canonical Wnt signalling pathway. Conversely, the 
Wnt signalling pathway can induce miR-34 expression 
[26] suggesting the existence of a feedback loop. Direct 
targets of miR-34a-5p also include CNNTB-1, with the 
miRanda prediction algorithm, indicating 3 potential 
binding sites in the 3’UTR of CTNNB1 (Ref Seq transcript 
NM_0019) where miR-34a-5p could be binding (Figure 5). 
Among other experimentally validated target genes, LEF1 
a key transcription factor in the Wnt signalling pathway is 
negatively regulated by miR-34a [27, 28].
With respect to circulating miR-34a-5p, a few 
studies have reported on serum levels and association 
with tumours including breast cancer, gastric cancer and 
lymphoma. In contrast to the reduced expression seen in 
many tumours, these studies found an upregulation of 
miR-34a in the serum of affected patients. Roth et al found 
an increase in circulating miR-34a in those patients with 
metastatic breast cancer compared to healthy controls [29]. 
Similarly, an increase was seen in patients with gastric 
cancer [30] although a reduced serum miR-34a level 
was reported in lymphoma [31]. Reduced expression in 
malignant tumour tissue contrast with the high expression 
of miR-34a-5p observed in DT tissue in this study. 
However, as DTs are not invasive tumours but benign 
myofibroblast tumours, it is possible that miR-34 has a 
role in driving fibrogenesis in DT patients. Compared 
to our knowledge on the role of miR-34 in malignant 
tumours, much less is known about the function of this 
miRNA in the context of fibrosis. However, In support of 
this hypothesis, up-regulation of miR-34 has been also 
associated with a number of fibrotic conditions including 
liver cirrhosis [32], myocardial infarction and fibrosis [33, 
34] and neuro-degenerative disorders [35]. Also, increased 
circulatory levels of miR-34a-5p were associated with 
intestinal fibrosis in Crohn’s disease using the same array 
platform [16].
Our study has provided proof-of-principle that 
miRNA biomarkers for DT management are a possibility. 
miR-34a-5p is a novel and lead candidate following 
validation of increased expression in two independent 
cohorts of serum and its elevated expression in tumours. 
Since a validated candidate has not been indicated before, 
a better understanding of the role of miR-34a-5p and its 
role in fibrogenesis is urgently required given the recent 
development of MRX34, a miR-34 analogue now in 
phase 1 clinical trial for the treatment of cancer [36, 37] 
and the existence of a miR-34 inhibitor [38]. The potential 
for off-target side effects of miRNA analogues also need 
careful consideration given that each miRNA is predicted 
to target multiple gene targets. Animal models and/or cell 
culture systems for DTs will be required to determine the 
functional significance of miR-34a-5p in DT development, 
although currently none exist. 
In conclusion, our study found upregulation of 
miR-34a-5p in the serum of DT patients relative to FAP 
controls, supporting its role as a non-invasive biomarker 
for DT. High levels of miR-34a-5p were also observed in 
the tumour tissue. These pathways have not been explored 
before in DT development. This miRNA may offer new 
treatment target pathways for future research into these 
rare and complex tumours. 
Figure 4. Immunohistochemistry p53 expression in 
desmoid tumour patients. A. (a). Low weighted score (case 1, 
supplementary table S2) and (b). high weighted score (case 2). 
Arrows indicating negative p53 blue staining cells and positive 
nuclei staining brown. x20 and x40 magnification. B. Correlation 
between miR-34a-5p and p53 expression in desmoid tumours.
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Figure 5. Interaction between miR-34a-5p and CTNNB1 as determined by miRtarBase.  A. Network constructed by miRtarBase showing 
the interaction between genes and miRNAs, B. Potential binding sites of miR-34a-5p in CTNNB1 3’UTR as predicted by miRanda and 
displayed by miRtarBase. C. miRNA-target interactions as predicted by miRanda and provided by miRtarBase. The alignment scores as 
well as a Minimum free energy (MFE) values that indicate the strength of the prediction are also shown.
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MATERIALS AND METHODS
Ethics statement
The study had appropriate ethical approval from 
London NRES committee and all participants gave 
their informed consent for a single blood test. Archival 
formalin-fixed paraffin-embedded (FFPE) DT tissue 
removed at surgery was obtained for assessment of miRNA 
expression using in-situ hybridisation (ISH) and to assess 
possible pathway targets, using immunohistochemistry 
(IHC). 
Serum collection
6ml of whole blood was collected in an EDTA bottle 
for each participant. Samples were centrifuged at 3000rpm 
for 10 mins within 1 hour of collection to achieve serum 
separation. Serum was then removed and stored in a 
cryovial at -80°C until required.
MicroRNA Arrays
RNA was extracted from 200 μl of serum and 
profiling of miRNAs performed by Qiagen (Germany) 
as previously described [14]. Quantification of serum 
miRNAs was achieved through SYBR-qPCR using 
miScript miRNA PCR 384HC array for serum (MIHS-
3106Z). The miRNA array panel set was selected from 
a previous panel used to investigate fibrosing Crohn’s 
disease [14]. Each array contained a panel of 384 primer 
sets for thoroughly researched miRNAs known to be 
highly expressed in serum and/or associated with altered 
expression in the context of other diseases. To enhance 
the detection of miRNAs present at low levels in serum, 
the arrays were performed using a pre-amplified cDNA set 
with a maximum cycle threshold (Ct) of 30 for all samples 
and miRNAs. An exogenous spiked in control (Cel-miR-
39-3p) was used for normalisation using the 2-∆Ct method 
and the data log2 transformed prior to statistical analysis 
to stabilise for variance and achieve a normal distribution. 
The delta Ct for miR-23 and miR-451a was used as a 
haemolysis indicator for the array samples; a value >7 
indicated significant risk of haemolysis [39]. 
Validation using single qPCR sera assays
Qiagen miRNeasy Serum/Plasma kit (Cat. No. 
217184) was used to extract RNA from 200 μl of serum 
and a synthetic RNA (Ce_miR-39_1) spike was added 
to enable normalisation of data. RNA was reversed 
transcribed and qPCR performed as described [16]. Each 
reaction was performed in duplicate and melt curve 
analysis undertaken to confirm a single PCR product. 
Levels of sera miRNA were normalised to corresponding 
values of Ce_miR-39_1 (MS00019789) spike using 
the 2-∆Ct method. These normalised data were then log2 
transformed prior to statistical analysis.
MicroRNA In-situ hybridisation 
The level of miRNA in DT FFPE tissue was 
investigated using miRNA ISH technology (Exiqon, 
Denmark). ISH probes were selected based on the sera 
PCR results and 4 μm sections from FFPE tissues were 
sectioned under RNAse clear conditions. A FFPE skin 
control (from a healthy patient without FAP) was also 
obtained and sectioned. To ensure adhesion, sections 
were heated on slides at 65°C for 10 mins before 
deparaffinising in xylene for 10 mins and hydrating in 
RNAse-free H
2
O. Sections were digested with 10ug/
ml proteinase K in PBS at 37°C for 30 minutes, washed 
in RNAse-free H
2
O and dehydrated through increasing 
concentrations of ethanol (70%, 95% and absolute), 1 
min each and then air-dried. Sections were then incubated 
with Double-DIG (digoxigenin) labelled Locked Nucleic 
Acid (LNA) ISH probes complementary to the selected 
miRNAs at 56°C for 2 hours. ISH probes were diluted 
from a 10 μM stock concentration.  Dilutions used for 
miR-34a-5p and miR-21-5p LNA ISH probes were 1:450 
and 1:240, respectively. A scrambled miRNA probe was 
used as a negative control at a dilution of 1:300. Slides 
subsequently underwent stringency washes at 56°C: once 
5X Saline sodium citrate (SSC) buffer, twice in 1X SSC, 
twice in 0.2X SSC and finally once in 0.2X SSC at room 
temperature. Slides were placed in blocking solution (1% 
triton, bovine serum albumin (BSA) in TBS) for 10 min. 
Anti-digoxigenein antibody (150U, Roche, Switzerland) 
at a 1:300 dilution (1% triton, BSA in TBS) was applied 
to the sections for 45 mins at room temperature, followed 
by TBS wash and rinse in RNAse-free H
2
O. Nitroblue 
tetrazolium and 5-bromo-4-chloro-3-indolyl phosphate 
(NBT/BCIP) reagent (Roche) was applied to detect signal 
overnight at 4°C.  Slides were washed briefly in tap water 
prior to counterstaining with nuclear fast red, dehydrating 
in increasing concentrations of ethanol and mounting in 
Eukitt (Fluka, Germany). 
P53 immunohistochemistry
FFPE 4 μm tumour sections were dewaxed in xylene 
and placed in absolute alcohol before application of an 
endogenous peroxide block for 10 mins and rehydrating 
through graded alcohol concentrations. Antigen retrieval 
was achieved by microwaving sections in a citrate buffer 
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(pH 8) for 20 mins. Non-reactive staining was blocked 
using rabbit serum (1:25 dilution) before p53 primary 
mouse antibody application (1:50, DAKO) for 45 mins. 
Sections were washed before the secondary rabbit anti-
mouse antibody (1:250) was applied for 45 mins. After 
further washing, antibody binding was detected using a 
diaminobenzidine reaction kit (kit K3468, DAKO, USA).
Tissue imaging and scoring 
IHC and ISH slides were analysed using a light 
microscope and scored by a pathologist according to 
stain intensity and proportion of positively staining cells. 
The percentage of neoplastic cells showing cytoplasmic 
staining at each of three levels of intensity (1: weak; 2: 
moderate; 3: strong) was determined for each marker. This 
yielded a total percentage of cells staining and enabled the 
calculation of a weighted score, where higher weight was 
given to higher intensities of staining. The weighted score 
was: (1 x the percentage staining at intensity 1) + (2 x the 
percentage staining at intensity 2) + (3 x the percentage 
staining at intensity 3).  On the basis of the weighted 
scores, cases were then defined as having high level, low 
level or no staining. 
Analysis of whole exome sequencing datasets of 
desmoid tumour samples
Tumour and germline DNA from three paired 
tumour-germline samples was isolated using standard 
methods from fresh frozen tumour tissue and peripheral 
blood leukocytes. Target exonic regions were captured 
using the Illumina Nextera rapid exome library prep kit 
(Illumina, UK). The captured regions were sequenced 
using Illumina HiSeq 2000. The sequence reads were 
aligned to the human genome reference using Burrows-
Wheeler Aligner (BWA) [40]. Tumour specific point 
mutations were detected by comparing tumour DNA 
to its paired germline using Varscan2 [41] and were 
subsequently annotated using ANNOVAR [42]. Mean 
sequencing coverage was calculated using the total 
number of reads in called positions for all tumour and 
germline samples. Tumour specific mutations were 
excluded if they were covered by less than 10 reads in 
either tumour or germline sample or had a somatic p-value 
of <0.05. The TargetScan predictive algorithm [20] was 
used to determine whether somatic mutations detected 
in 3’UTRs of miRNA target genes occurred within the 
miRNA biding sites. Supplementary Table 1 contains 
the list of target genes of the miRNAs (miR-34a-5p) as 
predicted by TargetScan v6.2.
Statistical analysis
Statistical analysis of miRNA array results 
was performed using the log2 transformed data. For 
comparison of demographic data and miRNA array 
discovery analysis, a two-tailed t test was used to 
determine differences between the two means, with alpha 
set to 0.05. For subsequent qPCR validation of differences 
between groups a one-tailed t test was applied.
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